Cancer Cell Membrane-Coated Nanoparticle Co-loaded with Photosensitizer and Toll-like Receptor 7 Agonist for the Enhancement of Combined Tumor Immunotherapy
ACS Nano · 12.09.2023 · 17 (17) · 16620-16632
DOI: 10.1021/acsnano.3c02724 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, online erschienen am 22.08.2023. Verfasst von Yanlin Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of New Drug Screening and NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceu…. Hauptthemen laut MEDLINE: Toll-Like Receptor 7, Nanoparticles. Die Arbeit wurde bisher 89-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Ministry of Science and Technology of the People's Republic of China, National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Tumor immunotherapy has shown considerable therapeutic potential in the past few years, but the clinical response rate of immunotherapy is less than 20%. Encountering the high heterogeneity of tumors, it will be a general trend to apply combined therapy for cancer treatment. Photodynamic therapy (PDT) transiently kills tumor cells by producing reactive oxygen species (ROS), while residual tumor cells are prone to metastasis, leading to tumor recurrence. In combination with tumor immunotherapy, it is hoped to awaken the host immune system and eradicate residual tumor cells. Herein, cancer cell membrane-coated nanoparticles as a platform to combine PDT, TLR7 agonist, and tumor antigen for the enhancement of tumor therapeutic efficacy are designed. The final biomimetic nanoparticles (CCMV/LTNPs) can specifically kill tumor cells through PDT, while strong host antitumor immune responses are elicited to eliminate residue tumor cells under the help of immune adjuvant and tumor antigen from the cancer cell membrane. In summary, a photoimmunotherapy strategy is designed that synergistically enhances the tumor therapeutic effects by killing tumor cells through PDT and activating host antitumor immune responses through the co-delivery of adjuvant and tumor antigen, which may offer a promising strategy for clinical immunotherapy in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of New Drug Screening and NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, People'…
- Department of Musculoskeletal Oncology, Center for Orthopaedic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510642, Guangdong, People's Republic of China.
ORCID-Profile: Yingfeng Tu, Kui Cheng
Förderung
- Ministry of Science and Technology of the People's Republic of China
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Chen, Y., Zhi, S., Ou, J., Gao, J., Zheng, L., Huang, M., Du, S., Shi, L., Tu, Y., & Cheng, K. (2023). Cancer Cell Membrane-Coated Nanoparticle Co-loaded with Photosensitizer and Toll-like Receptor 7 Agonist for the Enhancement of Combined Tumor Immunotherapy. ACS Nano, 17(17), 16620-16632. https://doi.org/10.1021/acsnano.3c02724
Vancouver
Chen Y, Zhi S, Ou J, Gao J, Zheng L, Huang M, et al. Cancer Cell Membrane-Coated Nanoparticle Co-loaded with Photosensitizer and Toll-like Receptor 7 Agonist for the Enhancement of Combined Tumor Immunotherapy. ACS Nano. 2023;17(17):16620-16632. doi:10.1021/acsnano.3c02724
BibTeX
@article{Chen2023,
author = {Chen, Yanlin and Zhi, Siying and Ou, Jiaxin and Gao, Junbin and Zheng, Lu and Huang, Meixin and Du, Shaohua and Shi, Liu and Tu, Yingfeng and Cheng, Kui},
title = {Cancer Cell Membrane-Coated Nanoparticle Co-loaded with Photosensitizer and Toll-like Receptor 7 Agonist for the Enhancement of Combined Tumor Immunotherapy},
journal = {ACS Nano},
year = {2023},
volume = {17},
number = {17},
pages = {16620--16632},
doi = {10.1021/acsnano.3c02724}
}
EUVIMED